As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
22 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:
22 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:
Jun '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -793 -793 |
2%
2%
|
EBIT (Operating Income) EBIT | -801 -801 |
3%
3%
|
Net Profit | -767 -767 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.
Head office | Virgin Islands, British |
CEO | Vladimir Coric |
Employees | 256 |
Founded | 2022 |
Website | www.biohaven.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.